MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

MDT

88.32

+0.83%↑

120.68

+3.05%↑

VEEV

157.23

-0.23%↓

HQY

80.02

+0.41%↑

TLRY

6.85

+1.63%↑

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

580.03 1.34

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

570.73

Max

581.55

Pagrindiniai rodikliai
By Trading Economics
Pajamos	26M 364M
Pardavimai	-9.3M 790M
P/E Sektoriaus vid.	20.102 66.418
Pelno marža	46.102
Darbuotojai	1,400
EBITDA	61M 524M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+11.17% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.1B 25B
Ankstesnė atidarymo kaina	578.69
Ankstesnė uždarymo kaina	580.03

Naujienos nuotaikos

By Acuity

50%

154 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

292.345 / 309.245 Palaikymas ir pasipriešinimas

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-13 23:25; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026-04-13 22:45; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026-04-13 18:03; UTC

Uždarbis

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026-04-13 23:58; UTC

Uždarbis

Review & Preview: Earnings Time -- Barrons.com

2026-04-13 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026-04-13 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026-04-13 23:20; UTC

Rinkos pokalbiai

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026-04-13 23:01; UTC

Uždarbis

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026-04-13 23:01; UTC

Uždarbis

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026-04-13 23:01; UTC

Uždarbis

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026-04-13 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026-04-13 21:26; UTC

Svarbiausios naujienos

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026-04-13 21:23; UTC

Uždarbis

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026-04-13 21:16; UTC

Uždarbis

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026-04-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-13 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026-04-13 19:59; UTC

Rinkos pokalbiai

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026-04-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026-04-13 19:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Precious Metals Market Talk on April 9

2026-04-13 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026-04-13 18:43; UTC

Rinkos pokalbiai

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

11.17% į viršų

12 mėnesių prognozė

Vidutinis 635.62 USD 11.17%

Aukščiausias 705 USD

Žemiausias 519 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

292.345 / 309.245Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

154 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.